Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection

O. Moran Mendoza
European Respiratory Journal 2011 38: 1237-1238; DOI: 10.1183/09031936.00182710
O. Moran Mendoza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: morano@queensu.ca
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

In their meta-analysis, Diel et al. [1] report a superior performance of interferon-γ release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI) compared with the tuberculin skin test (TST), the only other test available for diagnosing LTBI.

In the absence of a gold standard for LTBI, the proper assessment of the TST, IGRAs or any other future tests intended for the diagnosis of LTBI should focus on determining their capability for predicting the development of active tuberculosis (TB), i.e. the positive and negative predictive values for progression to active TB. Alternative evidence, such as the diagnostic accuracy of the test in active TB cases, is not appropriate for assessing the test’s capability to predict the development of TB.

Thus far, few studies have assessed the predictive capability of IGRAs and the TST; among them, only the study by Diel et al. [2] in Germany found IGRAs to be superior to the TST in predicting the development of TB (14.6% of IGRA-positive subjects versus 2.3% of TST-positive individuals developed TB during the 24-month follow-up period) [2]. All other studies comparing IGRAs and the TST, including two studies not included in the authors’ meta-analyses [3, 4], have reported a very similar rate of progression to active TB, ranging from 1.7 to 3.3% for IGRA-positive and 1.7 to 3.1% for TST-positive individuals, with follow-up periods from 19 to 24 months. The reasons for the discrepancy between these studies and the original study by Diel et al. [2] are not clear but could be due to different at-risk populations and, possibly, the type of tuberculin applied, as 0.1 mL Tuberculin-10-GT (Chiron Behring, Marburg, Germany) was used in an unknown proportion of subjects. The authors do not provide information on the equivalence of this tuberculin to the recommended purified protein derivative-S [5].

The main problem with most of these studies is the small number of study subjects and/or active TB cases developing among contacts: 6–15 TB cases were reported in all studies except one, which reported 26 cases [3].

Most studies that compared IGRAs and TST have reported low overall positive predictive values. Further studies are unlikely to show that IGRAs and the TST have better predictive capabilities because active TB develops in a minority of subjects who are considered to be infected, unless a different test or methodological approach is used.

In a large, longitudinal study in Canada that assessed the predictive value of the TST among untreated contacts of active TB cases, we found that 6.9% of household contacts and 48% of contacts 0–10 yrs of age with a positive TST developed TB [6]. These are much higher rates of progression to active TB than those reported in most studies for contacts with a positive IGRA.

Another potential limitation of IGRAs not considered by Diel et al. [1] is the high reversion rate (conversion from positive to negative) of 33–49% reported in studies where individuals were retested with IGRAs within a 1–3-month period [7, 8].

Until better tests are available, the usefulness of the TST and IGRAs, whether alone or in combination, should ideally be assessed by cost-effectiveness studies in different high-risk groups for developing TB: household contacts, contacts 0–10 yrs of age and immunosuppressed contacts of active TB cases [9]. Future studies are therefore needed to determine whether IGRAs, the TST or both are currently the best option in predicting the risk of developing TB.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2011

REFERENCES

  1. ↵
    1. Diel R,
    2. Goletti D,
    3. Ferrara G,
    4. et al
    . Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88–99.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Diel R,
    2. Loddenkemper R,
    3. Meywald-Walter K,
    4. et al
    . Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164–1170.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Hill PC,
    2. Jackson-Sillah DJ,
    3. Fox A,
    4. et al
    . Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3: e1379.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bakir M,
    2. Millington KA,
    3. Soysal A,
    4. et al
    . Prognostic value of a T-cell-based, interferon-γ biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149: 777–787.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Migliori GB,
    2. Raviglione MC,
    3. Schaberg T,
    4. et al
    . Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 1999; 14: 978–992.
    OpenUrlFREE Full Text
  6. ↵
    1. Moran-Mendoza O,
    2. Marion SA,
    3. Elwood K,
    4. et al
    . Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts. Int J Tuberc Lung Dis 2007; 11: 1014–1020.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Hill PC,
    2. Brookes RH,
    3. Fox A,
    4. et al
    . Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007; 4: e192.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Gandra S,
    2. Scott WS,
    3. Somaraju V,
    4. et al
    . Questionable effectiveness of the QuantiFERON-TB Gold Test (Cellestis) as a screening tool in healthcare workers. Infect Control Hosp Epidemiol 2010; 31: 1279–1285.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Moran-Mendoza O,
    2. Marion SA,
    3. Elwood K,
    4. et al
    . Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 2010; 14: 1112–1119.
    OpenUrlPubMed
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 5 Table of Contents
European Respiratory Journal: 38 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection
O. Moran Mendoza
European Respiratory Journal Nov 2011, 38 (5) 1237-1238; DOI: 10.1183/09031936.00182710

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection
O. Moran Mendoza
European Respiratory Journal Nov 2011, 38 (5) 1237-1238; DOI: 10.1183/09031936.00182710
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endothelial to mesenchymal transition as novel feature of pulmonary fibrosis
  • Transitioning endothelial cells contribute to pulmonary fibrosis
  • Treatable traits in ILD: why not consider acute exacerbations?
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society